BCL-2
38 programs · 38 companies
Programs
38
Companies
38
Active Trials
22
Targeting BCL-2
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| RHH-8550 | Roche | Approved | CRCRB | |
| Rimaglumide | Biogen | Phase 1/2 | IgAN | |
| ARG-4339 | Argenx | Phase 2 | MDSSchizophrenia | |
| GMA-729 | Genmab | Phase 2 | SLETTR Amyloidosis | |
| HAL-996 | Halozyme | Phase 1/2 | PompeHuntington's | |
| Bemaderotide | Revolution Medicines | Phase 3 | ADPKDCeliac | |
| Zenonaritide | Arvinas | Phase 1/2 | ALL | |
| Zoriosocimab | Y-mAbs | Phase 3 | Ewing Sarcoma | |
| EVT-1993 | Evotec | Phase 1/2 | MCL | |
| ATO-3461 | Alligator Bio | Phase 1 | SCD | |
| NCI-IIT-512 | NCI | Approved | ALL | |
| CHI-IIT-120 | Children's Oncology Grp | Phase 2/3 | GIST | |
| FRE-IIT-474 | Fred Hutch Cancer Ctr | Phase 2 | HS | |
| EQR-8061 | EQRx | Phase 1 | MCCAML | |
| ELE-7872 | Elevation Onc | Phase 2/3 | CTCLACC | |
| Tixalucimab | Agenus | Phase 2 | RBDMD | |
| Nidarelsin | Metsera | Phase 2/3 | TTR AmyloidosisOvarian Ca | |
| VAX-4941 | Vaxxinity | Phase 1 | WMMG | |
| Rimazasiran | Chimerix | Approved | RAT2D | |
| Mirirelsin | Durect (Innocoll) | Preclinical | OCD | |
| Capirasimod | Aileron Therapeutics | Phase 3 | Obesity | |
| KMD-8521 | Kamada | Preclinical | LGSHeart Failure | |
| Niracagene | Prevail (Lilly) | Preclinical | Parkinson'sHeart Failure | |
| Sovafutibatinib | Pharmacyclics (AbbVie) | Phase 1 | Huntington's | |
| Doxazanubrutinib | Celltrion | Phase 1 | CholangiocarcinomaRCC | |
| DUK-IIT-769 | Duke Cancer | Approved | ALS | |
| Cevifutibatinib | Arcellx | Phase 1 | PompeACC | |
| MIM-9797 | Mimetogen | Phase 2/3 | NB | |
| Rimacagene | Scribe Ther | Preclinical | EoEThymoma | |
| PSI-4605 | PsiOxus (now Akeso) | Preclinical | Bladder CaGBM | |
| 418-6056 | Mitsubishi Tanabe | Phase 1/2 | NBADPKD | |
| 006-2012 | GC Pharma | Phase 1/2 | IPFCLL | |
| Nirazumab | Anteris Tech | Phase 1 | Angelman | |
| Zorinesiran | Twist Bioscience | Phase 1/2 | IgAN | |
| SIA-643 | Siam Bioscience | Phase 1 | MCCMS | |
| Rilucilimab | Agilent Technologies | Phase 1/2 | DMDOvarian Ca | |
| ANG-3408 | Angelini Pharma | Phase 2/3 | PSPMCL | |
| VEE-457 | Veeva Systems | Phase 1 | CFADHD |